Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol vs BAT for Carbapenem-Resistant Infections
NCT02714595Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of cefiderocol in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP), complicated urinary tract infection (cUTI), sepsis, sponsored by Shionogi & Co., Ltd.. Started Sep 2016; status: completed.
02
Drugs
cefiderocol
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)complicated urinary tract infection (cUTI)sepsis
Beyond the preview
Go deeper on NCT02714595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714595.